TI
CERE

Trexquant Investment’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Trexquant Investment’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-14,397
Closed -$314K – 1882
2023
Q3 		$314K Buy
+14,397
New +$360K 0.01% 1204
2022
Q1 		– Sell
-10,727
Closed -$348K – 1819
2021
Q4 		$348K Sell
10,727
-17,474
-62% -$617K 0.02% 843
2021
Q3 		$832K Buy
+28,201
New +$792K 0.07% 372

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Trexquant Investment's CERE Position: Q4 2023 in Review

Trexquant Investment sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q4 2023, closing a stake of 14,397 shares — an estimated $314K sold.

Trexquant Investment first reported a position in CERE in Q3 2021 and held it in 3 quarters. The position peaked at $832K in Q3 2021. 195 funds tracked by Wall St. Rank hold CERE as of Q4 2023.

  • Trexquant Investment reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Trexquant Investment sold 14,397 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q4 2023, an estimated $314K.
  • Trexquant Investment first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2021 and held it in 3 quarters.
  • Trexquant Investment's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $832K in Q3 2021.
  • 195 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q4 2023.

Based on Trexquant Investment's 13F filing for Q4 2023, filed 9 Feb 2024.